Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness.

Humans Bronchodilator Agents / therapeutic use Asthma / diagnosis Forced Expiratory Volume / physiology Vital Capacity / physiology Adrenal Cortex Hormones / therapeutic use
Antibody Benralizumab Biologic Bronchodilator responsiveness Mepolizumab Severe asthma

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 04 02 2022
revised: 04 06 2022
accepted: 07 07 2022
pubmed: 24 7 2022
medline: 15 12 2022
entrez: 23 7 2022
Statut: ppublish

Résumé

Positive bronchodilator responsiveness (BDR) (change in forced expiratory volume in 1 second [ΔFEV To investigate whether the response to anti-IL5/anti-IL5Rα therapies differs between patients with positive and negative BDR at baseline. Retrospective multicenter analysis of treatment outcomes in patients with severe asthma receiving anti-IL-5/anti-IL-5Rα stratified for baseline BDR. Of 133 patients included, 37 had a positive and 96 had a negative BDR at baseline. Following anti-IL-5/anti-IL-5Rα treatment, FEV Both groups improved following treatment with similar responses concerning reduction of OCS therapy, exacerbations, and improvement of symptom control. Pulmonary function also improved in both groups during anti-IL-5/anti-IL-5Rα treatment, with differences in response patterns noted.

Sections du résumé

BACKGROUND BACKGROUND
Positive bronchodilator responsiveness (BDR) (change in forced expiratory volume in 1 second [ΔFEV
OBJECTIVE OBJECTIVE
To investigate whether the response to anti-IL5/anti-IL5Rα therapies differs between patients with positive and negative BDR at baseline.
METHODS METHODS
Retrospective multicenter analysis of treatment outcomes in patients with severe asthma receiving anti-IL-5/anti-IL-5Rα stratified for baseline BDR.
RESULTS RESULTS
Of 133 patients included, 37 had a positive and 96 had a negative BDR at baseline. Following anti-IL-5/anti-IL-5Rα treatment, FEV
CONCLUSIONS CONCLUSIONS
Both groups improved following treatment with similar responses concerning reduction of OCS therapy, exacerbations, and improvement of symptom control. Pulmonary function also improved in both groups during anti-IL-5/anti-IL-5Rα treatment, with differences in response patterns noted.

Identifiants

DOI: 10.1016/j.jaip.2022.07.007 PMID: 35870725
pubmed: 35870725
pii: S2213-2198(22)00706-1
doi: 10.1016/j.jaip.2022.07.007
pii:
doi:

Substances chimiques

Bronchodilator Agents 0
Adrenal Cortex Hormones 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3174-3183

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Carlo Mümmler (C)

Department of Medicine V, University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center (CPC-M), LMU and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.

Hendrik Suhling (H)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Julia Walter (J)

Department of Medicine V, University Hospital, LMU Munich, Germany.

Nikolaus Kneidinger (N)

Department of Medicine V, University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center (CPC-M), LMU and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.

Roland Buhl (R)

Clinical Research Centre for Respiratory Medicine, Mainz, Germany.

Moritz Z Kayser (MZ)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Nora Drick (N)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Jürgen Behr (J)

Department of Medicine V, University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center (CPC-M), LMU and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.

Tobias Welte (T)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover, Germany.

Stephanie Korn (S)

IKF Pneumologie Mainz, Mainz, Germany; Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, Germany.

Katrin Milger (K)

Department of Medicine V, University Hospital, LMU Munich, Germany; Comprehensive Pneumology Center (CPC-M), LMU and Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich, Germany. Electronic address: Katrin.Milger@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Overall Response to Anti-IL-5/Anti-IL5-Rα...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents de l'appareil respiratoire › Antiasthmatiques › Bronchodilatateurs › Overall Response to Anti-IL-5/Anti-IL5-Rα...
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Hypersensibilité respiratoire › Asthme › Overall Response to Anti-IL-5/Anti-IL5-Rα...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Ventilation pulmonaire › Volume expiratoire maximal par seconde › Overall Response to Anti-IL-5/Anti-IL5-Rα...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Capacité pulmonaire totale › Capacité vitale › Overall Response to Anti-IL-5/Anti-IL5-Rα...
questionsmedicales.fr › Hormones corticosurrénaliennes › Overall Response to Anti-IL-5/Anti-IL5-Rα...